Promethazine 50mg/2ml solution for injection ampoules

5mg/5ml

Promethazine 5mg/5ml oral suspension

Oral suspension

5mg/5ml

Alimemazine 10mg/5ml oral solution sugar free

10mg/5ml

Alimemazine 7.5mg/5ml oral solution sugar free

7.5mg/5ml

Alimemazine 30mg/5ml oral solution sugar free

30mg/5ml

Drug monograph — bnf.nice.org.uk

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Promethazine hydrochloride

BNF

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Promethazine hydrochloride

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

16324511000001109

dm+d ID

16324511000001109

VTM (Virtual Therapeutic Moiety)

13868411000001104

VMP (Virtual Medicinal Product)

16324511000001109

BNF code

03040100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

R06AD02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

15 found

Half-life

12-15h

Mechanism

Promethazine is a an antagonist of histamine H1, post-synaptic mesolimbic dopami…

Food interactions

1 warning

Human targets

14 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

25mg

A 25mg dose of intramuscular promethazine reaches a C_max of 22ng/mL.
[A189925]…

Half-life

12-15h

The elimination half life of promethazine is approximately 12-15h.
[A189925]

Protein binding

93%

Promethazine is 93% protein bound in serum,[A190033] mostly to albumin.
[A190132]

Volume of distribution

970L

The volume of distribution of promethazine is approximately 970L or 30L/kg.
[A189925]

Metabolism

Promethazine is predominantly metabolized to promethazine sulfoxide, and minorly to desmethylpromethazine and a hydroxy metabolite.
[A183788][A189925]…

Elimination

0.64%

An intravenous dose of promethazine is 0.64% eliminated in the urine as the unchanged parent drug, 0.02-2.02%…

Clearance

1.14L

The intravenous clearance of promethazine is approximately 1.14L/min.
[A189925]…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.[A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907][A190153][A190159][A190150][A190171]

Promethazine was granted FDA approval before 29 March 1951.[A190177][L4000]

Properties:

solid

Avg. mass: 284.42 Da

View FDA drug label

DrugBank indication

Promethazine tablets and suppositories are indicated to treat rhinitis, allergic conjunctivitis, allergic reactions to blood or plasma, dermographism, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness, and allergic skin reactions.
[A189907][L4000]
Promethazine cough syrup with phenylephrine and codeine is indicated to relieve cough and upper respiratory symptoms, and nasal congestion associated with allergy or the common cold.
[L11326]

Also known as(475)

(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine

10-(2-Dimethylaminopropyl)phenothiazine

10-[2-(dimethylamino)propyl]phenothiazine

N-(2'-dimethylamino-2'-methyl)ethylphenothiazine

N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine

N,N,α-trimethyl-10H-phenothiazine-10-ethanamine

Proazamine

Prometazina

Dosage forms(75)

Tablet (Oral)

Cream (Topical) — 2 %

Solution (Oral) — 20 mg/mL

— 25 mg/mL

Elixir (Oral) — 9 mg/5ml

Injection (Intramuscular; Intravenous) — 50 mg

Syrup (Oral) — 9 mg/5ml

Injection, solution (Parenteral) — 50 MG/2ML

Molecular properties(18)

Drug interactions(2075)

Known interactions with other medications. Always consult a healthcare professional.

Buprenorphine

Moderate

DB00921

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.

Dronabinol

Unknown severity

DB00470

The serum concentration of Dronabinol can be increased when it is combined with Promethazine.

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.

Hydrocodone

Moderate

DB00956

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Promethazine can be increased when used in combination with Magnesium sulfate.

Methotrimeprazine

Moderate

DB01403

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.

Orphenadrine

Moderate

DB01173

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Paraldehyde

Moderate

DB09117

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Promethazine.

Rotigotine

Moderate

DB05271

Promethazine may increase the sedative activities of Rotigotine.

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Promethazine.

Sodium oxybate

Moderate

DB09072

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Suvorexant

Moderate

DB09034

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Tapentadol

Moderate

DB06204

Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.

Thalidomide

Moderate

DB01041

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Zolpidem

Moderate

DB00425

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Aclidinium

Unknown severity

DB08897

The risk or severity of adverse effects can be increased when Promethazine is combined with Aclidinium.

Mianserin

Moderate

DB06148

Mianserin may increase the anticholinergic activities of Promethazine.

Mirabegron

Unknown severity

DB08893

The risk or severity of urinary retention can be increased when Promethazine is combined with Mirabegron.

Potassium chloride

Unknown severity

DB00761

The risk or severity of gastrointestinal ulceration can be increased when Promethazine is combined with Potassium chloride.

Pramlintide

Unknown severity

DB01278

The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Promethazine.

Secretin porcine

Moderate

DB09527

The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Promethazine.

Tiotropium

Unknown severity

DB01409

The risk or severity of adverse effects can be increased when Promethazine is combined with Tiotropium.

Topiramate

Unknown severity

DB00273

The risk or severity of hyperthermia and oligohydrosis can be increased when Promethazine is combined with Topiramate.

Umeclidinium

Unknown severity

DB09076

The risk or severity of adverse effects can be increased when Promethazine is combined with Umeclidinium.

Amisulpride

Moderate

DB06288

Promethazine may increase the antipsychotic activities of Amisulpride.

Quinagolide

Moderate

DB09097

The therapeutic efficacy of Quinagolide can be decreased when used in combination with Promethazine.

Sulpiride

Moderate

DB00391

Promethazine may increase the antipsychotic activities of Sulpiride.

Benzylpenicilloyl polylysine

Moderate

DB00895

Promethazine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.

Betahistine

Moderate

DB06698

The therapeutic efficacy of Betahistine can be decreased when used in combination with Promethazine.

Hyaluronidase (ovine)

Moderate

DB00070

The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promethazine.

Hyaluronidase (human recombinant)

Moderate

DB06205

The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Promethazine.

Hyaluronidase

Moderate

DB14740

The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.

Methadone

Unknown severity

DB00333

The risk or severity of adverse effects can be increased when Methadone is combined with Promethazine.

Lithium hydroxide

Moderate

DB14506

Lithium hydroxide may increase the neurotoxic activities of Promethazine.

Lithium citrate

Moderate

DB14507

Lithium citrate may increase the neurotoxic activities of Promethazine.

Mequitazine

Moderate

DB01071

Promethazine may increase the arrhythmogenic activities of Mequitazine.

Thiopental

Unknown severity

DB00599

The risk or severity of adverse effects can be increased when Promethazine is combined with Thiopental.

Atomoxetine

Moderate

DB00289

The metabolism of Atomoxetine can be decreased when combined with Promethazine.

Atazanavir

Moderate

DB01072

Promethazine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.

Bosutinib

Moderate

DB06616

Promethazine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.

Cefditoren

Moderate

DB01066

Promethazine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy.

Cefpodoxime

Moderate

DB01416

Promethazine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.

Cefuroxime

Moderate

DB01112

Promethazine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.

Dabrafenib

Unknown severity

DB08912

The serum concentration of Promethazine can be decreased when it is combined with Dabrafenib.

Dasatinib

Moderate

DB01254

Promethazine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.

Delavirdine

Moderate

DB00705

Promethazine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.